Heron Therapeutics, Inc. (HRTX)
0.3439
+0.01
(+4.21%)
USD |
NASDAQ |
Sep 04, 16:00
0.355
+0.01
(+3.23%)
After-Hours: 20:00
Heron Therapeutics SG&A Expense (TTM) : 104.50M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 104.50M |
| March 31, 2026 | 105.11M |
| December 31, 2025 | 103.67M |
| September 30, 2025 | 101.18M |
| June 30, 2025 | 97.61M |
| March 31, 2025 | 99.08M |
| December 31, 2024 | 100.48M |
| September 30, 2024 | 100.90M |
| June 30, 2024 | 102.15M |
| March 31, 2024 | 111.07M |
| December 31, 2023 | 116.66M |
| September 30, 2023 | 119.74M |
| June 30, 2023 | 123.32M |
| March 31, 2023 | 119.00M |
| December 31, 2022 | 119.95M |
| September 30, 2022 | 127.62M |
| June 30, 2022 | 134.44M |
| March 31, 2022 | 135.48M |
| December 31, 2021 | 127.33M |
| September 30, 2021 | 121.01M |
| June 30, 2021 | 108.02M |
| March 31, 2021 | 100.27M |
| December 31, 2020 | 106.08M |
| September 30, 2020 | 108.32M |
| June 30, 2020 | 111.89M |
| Date | Value |
|---|---|
| March 31, 2020 | 119.91M |
| December 31, 2019 | 127.66M |
| September 30, 2019 | 126.06M |
| June 30, 2019 | 124.06M |
| March 31, 2019 | 111.37M |
| December 31, 2018 | 93.87M |
| September 30, 2018 | 88.02M |
| June 30, 2018 | 84.44M |
| March 31, 2018 | 84.66M |
| December 31, 2017 | 82.16M |
| September 30, 2017 | 77.85M |
| June 30, 2017 | 75.35M |
| March 31, 2017 | 70.18M |
| December 31, 2016 | 69.03M |
| September 30, 2016 | 65.29M |
| June 30, 2016 | 56.05M |
| March 31, 2016 | 47.11M |
| December 31, 2015 | 35.74M |
| September 30, 2015 | 26.24M |
| June 30, 2015 | 22.22M |
| March 31, 2015 | 19.74M |
| December 31, 2014 | 19.44M |
| September 30, 2014 | 18.38M |
| June 30, 2014 | 20.93M |
| March 31, 2014 | 21.25M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Tonix Pharmaceuticals Holding Corp. | 125.96M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Anika Therapeutics, Inc. | 52.67M |
| Savara, Inc. | 56.71M |